<?xml version="1.0" encoding="UTF-8"?>
<Pathway xmlns="http://pathvisio.org/GPML/2013a" Name="Neurodegenerative Diseases" Organism="Homo sapiens">
  <Comment Source="WikiPathways-description">Neurodegenerative diseases manifest as the progressive dysfunction and loss of neurons, which is frequently accompanied by formation of misfolded protein deposits in the brain. Classification of neurodegenerative diseases is based on clinical symptoms, which depend on the anatomical region affected by neuronal dysfunction, the identity of misfolded proteins and cellular and subcellular pathology.&lt;br&gt;In Alzheimerâ€™s disease (AD), beta-amyloid protein (APP) deposits form in the extracellular space, where they can make plaques, while abnormally phosphorylated tau protein (MAPT) accumulates in neuronal cells.&lt;br&gt;Beside AD, neuronal and/or glial inclusions of hyperphosphorylated tau are also found in Pick disease (PiD), neurofibrillary tangle-dementia (NFT), primary age-related tauopathy (PART), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD) and globular glial tauopathies (GGT).&lt;br&gt;In prion disease, such as Creutzfeldt-Jakob disease, deposits of PrP protein are formed mostly in the extracellular and presynaptic space. PrP deposits in neuronal cell bodies are mainly confined to endosomes and lysosomes, which is attributed to neuronal uptake of pathological proteins and intercellular prion spreading.&lt;br&gt;In Parkinson disease (PD) and dementia with Lewy bodies (DLB), deposits of alpha-synuclein (SNCA) are formed in the cytoplasm of neuronal cell bodies and neurites. In multiple system atrophy (MSA), deposits of alpha-synuclein form in the cytoplasm of glial cells (Papp-Lantos bodies).&lt;br&gt;Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are characterized by ubiquitin-positive cytoplasmic inclusions of TAR DNA-binding protein 43 (TARDBP, commonly known as TDP-43), a protein that normally localizes to the nucleus. Pathological TDP-43 inclusions have been associated with the TDP-43 gene mutations, as well as mutations in several other genes, including C9orf72, GRN, VCP, SQSTM1, DCTN1 and OPTN. TDP-43 inclusions have also been reported in AD, DLB, hippocampal sclerosis (HS) and chronic traumatic encephalopathy.&lt;br&gt;FUS protein-positive inclusion bodies are found in familial ALS, caused by mutations in the FUS gene, as well as in a small subgroup of FTLD-related diseases. FUS-positive inclusions may be accompanied by FET protein-positive inclusions.&lt;br&gt;For a detailed review of molecular pathology of neurodegenerative diseases, please refer to Kovacs 2016.&lt;br&gt;Within this broad domain, the process by which APP-triggered deregulation of CDK5 (cyclin-dependent kinase 5) triggers multiple neurodegenerative pathways associated with Alzheimer's disease has been annotated.
 View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=8863678 Reactome].</Comment>
  <Comment Source="Reactome-Converter">Pathway is converted from Reactome ID: 8863678</Comment>
  <Comment Source="Reactome-version">Reactome version: 88</Comment>
  <Comment Source="Reactome Author">Reactome Author: Orlic-Milacic, Marija</Comment>
  <BiopaxRef>a3f</BiopaxRef>
  <Attribute Key="reactome_id" Value="8863678" />
  <Graphics BoardWidth="326.0" BoardHeight="253.0" />
  <DataNode TextLabel="Deregulated CDK5&#xA;triggers multiple&#xA;neurodegenerative&#xA;pathways in&#xA;Alzheimer's disease&#xA;models" GraphId="a50f4" Type="Pathway">
    <Comment Source="Reactome">Post-mitotic neurons do not have an active cell cycle. However, deregulation of Cyclin Dependent Kinase-5 (CDK5) activity in these neurons can aberrantly activate various components of cell cycle leading to neuronal death (Chang et al. 2012). Random activation of cell cycle proteins has been shown to play a key role in the pathogenesis of several neurodegenerative disorders (Yang et al. 2003, Lopes et al. 2009). CDK5 is not activated by the canonical cyclins, but binds to its own specific partners, CDK5R1 and CDK5R2 (aka p35 and p39, respectively) (Tsai et al. 1994, Tang et al. 1995). Expression of p35 is nearly ubiquitous, whereas p39 is largely expressed in the central nervous system. A variety of neurotoxic insults such as beta-amyloid (A-beta), ischemia, excitotoxicity and oxidative stress disrupt the intracellular calcium homeostasis in neurons, thereby leading to the activation of calpain, which cleaves p35 into p25 and p10 (Lee et al. 2000). p25 has a six-fold longer half-life compared to p35 and lacks the membrane anchoring signal, which results in its constitutive activation and mislocalization of the CDK5:p25 complex to the cytoplasm and the nucleus. There, CDK5:p25 is able to access and phosphorylate a variety of atypical targets, triggering a cascade of neurotoxic pathways that culminate in neuronal death. One such neurotoxic pathway involves CDK5-mediated random activation of cell cycle proteins which culminate in neuronal death. Exposure of primary cortical neurons to oligomeric beta-amyloid (1-42) hyper-activates CDK5 due to p25 formation, which in turn phosphorylates CDC25A, CDC25B and CDC25C. CDK5 phosphorylates CDC25A at S40, S116 and S261; CDC25B at S50, T69, S160, S321 and S470; and CDC25C at T48, T67, S122, T130, S168 and S214. CDK5-mediated phosphorylation of CDC25A, CDC25B and CDC25C not only increases their phosphatase activities but also facilitates their release from 14-3-3 inhibitory binding. CDC25A, CDC25B and CDC25C in turn activate CDK1, CDK2 and CDK4 kinases causing neuronal death. Consistent with this mechanism, higher CDC25A, CDC25B and CDC25C activities were observed in human Alzheimer's disease (AD) clinical samples, as compared to age-matched controls. Inhibition of CDC25 isoforms confers neuroprotection to beta-amyloid toxicity, which underscores the contribution of this pathway to AD pathogenesis</Comment>
    <BiopaxRef>d48</BiopaxRef>
    <BiopaxRef>f3c</BiopaxRef>
    <BiopaxRef>c10</BiopaxRef>
    <BiopaxRef>a93</BiopaxRef>
    <BiopaxRef>cea</BiopaxRef>
    <BiopaxRef>bc2</BiopaxRef>
    <Attribute Key="org.pathvisio.DoubleLineProperty" Value="Double" />
    <Graphics CenterX="194.5" CenterY="166.0" Width="203.0" Height="114.0" ZOrder="32768" FontSize="10" Valign="Middle" LineThickness="0.0" Color="14961e" />
    <Xref Database="Reactome" ID="R-HSA-8862803" />
  </DataNode>
  <InfoBox CenterX="0.0" CenterY="0.0" />
  <Biopax>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a3f">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">26848654</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Molecular Pathological Classification of Neurodegenerative Diseases: Turning towards Precision Medicine.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Kovacs GG.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="d48">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">22899714</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Chang KH, Vincent F, Shah K.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="f3c">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">12684440</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer's disease.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Yang Y, Mufson EJ, Herrup K.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="c10">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">19519302</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Cell cycle re-entry in Alzheimer's disease: a major neuropathological characteristic?</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lopes JP, Oliveira CR, Agostinho P.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="a93">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">8090221</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tsai LH, Delalle I, Caviness VS, Chae T, Harlow E.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="cea">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">7592934</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">An isoform of the neuronal cyclin-dependent kinase 5 (Cdk5) activator.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Tang D, Yeung J, Lee KY, Matsushita M, Matsui H, Tomizawa K, Hatase O, Wang JH.</bp:AUTHORS>
    </bp:PublicationXref>
    <bp:PublicationXref xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" rdf:id="bc2">
      <bp:ID rdf:datatype="http://www.w3.org/2001/XMLSchema#string">10830966</bp:ID>
      <bp:DB rdf:datatype="http://www.w3.org/2001/XMLSchema#string">PubMed</bp:DB>
      <bp:TITLE rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Neurotoxicity induces cleavage of p35 to p25 by calpain.</bp:TITLE>
      <bp:AUTHORS rdf:datatype="http://www.w3.org/2001/XMLSchema#string">Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH.</bp:AUTHORS>
    </bp:PublicationXref>
  </Biopax>
</Pathway>

